Formations of, Acquisitions by, and Mergers of Savings and Loan Holding Companies, 42401-42402 [2020-15182]
Download as PDF
<![CDATA[
Federal Register / Vol. 85, No. 135 / Tuesday, July 14, 2020 / Notices
as IPAC members of the opportunity to
be considered for the IPAC.
DATES: Statements of Interest received
on or before September 14, 2020 will be
given consideration for selection to the
IPAC for appointment in 2020.
ADDRESSES: Individuals who are
interested in being considered for the
IPAC may submit a Statement of Interest
to IPAC@frb.gov. The Statement of
Interest collects only contact
information. Candidates may also
choose to provide additional
information for consideration as part of
their interest in serving on the IPAC.
Any such supplemental materials may
also be emailed to IPAC@frb.gov. The
Privacy Act Statement for IPAC Member
Selection, which describes the
purposes, authority, effects of
nondisclosure, and uses of this
information, can be found at https://
www.federalreserve.gov/aboutthefed/
ipac-privacy.htm.
Submissions may also be mailed to
the Board of Governors of the Federal
Reserve System, Attn: Insurance Policy
Advisory Committee, 20th Street and
Constitution Ave. NW, Washington, DC
20551.
FOR FURTHER INFORMATION CONTACT:
Thomas Sullivan, Associate Director,
(202) 475–7656; Linda Duzick, Manager,
(202) 728–5881; or Jan Bauer, Sr.
Insurance Policy Analyst, (202) 475–
7697, Division of Supervision and
Regulation; or IPAC@frb.gov.
SUPPLEMENTARY INFORMATION: The
Economic Growth, Regulatory Relief,
and Consumer Protection Act
established at the Board an Insurance
Policy Advisory Committee (IPAC) to
advise the Board on international
capital standards and other insurance
matters. This document advises
individuals of the opportunity to be
considered for appointment to the IPAC.
To assist with the selection of IPAC
members, the Board will consider the
information submitted by the candidate
along with other information that it
independently obtains.
members only for their actual travel
expenses subject to Board policy.
Statement of Interest
The Statement of Interest for the IPAC
collects the following contact
information about the candidate:
• Full name;
• Address;
• Phone number; and
• Email address.
At their option, candidates may also
provide additional information for
consideration as part of their interest in
serving on the IPAC.
Qualifications
IPAC candidates should be insurance
experts. The Board seeks a diverse set of
expert perspectives from the various
sectors of the U.S. insurance industry
including life insurance, property and
casualty insurance and reinsurance,
agents and brokers, academics,
consumer advocates, and experts on
issues facing underserved insurance
communities and consumers. The Board
also seeks relevant actuarial, legal,
regulatory, and accounting expertise, as
well as expertise on lines of business
underwritten by its currently supervised
population of insurance institutions.
IPAC members must be willing and
able to participate in conference calls
and prepare for and attend meetings in
person. IPAC membership and
attendance is not delegable.
By order of the Board of Governors of the
Federal Reserve System, acting through the
Director of the Division of Supervision &
Regulation under delegated authority, June
29, 2020.
Ann Misback,
Secretary of the Board.
[FR Doc. 2020–15102 Filed 7–13–20; 8:45 am]
BILLING CODE P
FEDERAL RESERVE SYSTEM
Formations of, Acquisitions by, and
Mergers of Bank Holding Companies;
Correction
Council Size and Terms
Correction
The IPAC will have no more than 21
members. The initial IPAC members,
selected in 2019, have staggered terms
to provide the IPAC with continuity.
Members chosen at subsequent times
will be appointed to three-year terms
unless the appointment is made to fill
an unexpired term. Selected members
will serve a three-year term on IPAC
commencing on January 1, 2021, unless
selected to fill an unexpired term. The
Board will provide a nominal
honorarium and will reimburse IPAC
In the Federal Register of June 24,
2020, in FR Doc. 2020–13633,
‘‘Formations of, Acquisitions by, and
Mergers of Bank Holding Companies’’
pursuant to the Bank Holding Company
Act of 1956 and the Board’s Regulation
Y, under the heading, Federal Reserve
Bank of Chicago, Katz Acquisition
Corporation, LLC, Tampa, Florida;, on
page 37947, in the first column, at the
end of the first full paragraph, the
comment period end date is corrected to
read July 24, 2020.
VerDate Sep<11>2014
17:58 Jul 13, 2020
Jkt 250001
PO 00000
Frm 00056
Fmt 4703
Sfmt 4703
42401
Interested persons may view the
notice and submit comments as
provided in 85 FR 37946 (June 24, 2020)
no later than July 24, 2020.
Board of Governors of the Federal Reserve
System, July 7, 2020.
Yao-Chin Chao,
Assistant Secretary of the Board.
[FR Doc. 2020–14985 Filed 7–13–20; 8:45 am]
BILLING CODE P
FEDERAL RESERVE SYSTEM
Formations of, Acquisitions by, and
Mergers of Savings and Loan Holding
Companies
The companies listed in this notice
have applied to the Board for approval,
pursuant to the Home Owners’ Loan Act
(12 U.S.C. 1461 et seq.) (HOLA),
Regulation LL (12 CFR part 238), and
Regulation MM (12 CFR part 239), and
all other applicable statutes and
regulations to become a savings and
loan holding company and/or to acquire
the assets or the ownership of, control
of, or the power to vote shares of a
savings association.
The public portions of the
applications listed below, as well as
other related filings required by the
Board, if any, are available for
immediate inspection at the Federal
Reserve Bank(s) indicated below and at
the offices of the Board of Governors.
This information may also be obtained
on an expedited basis, upon request, by
contacting the appropriate Federal
Reserve Bank and from the Board’s
Freedom of Information Office at
https://www.federalreserve.gov/foia/
request.htm. Interested persons may
express their views in writing on
whether the proposed transaction
complies with the standards
enumerated in the HOLA (12 U.S.C.
1467a(e)).
Comments regarding each of these
applications must be received at the
Reserve Bank indicated or the offices of
the Board of Governors, Ann E.
Misback, Secretary of the Board, 20th
Street and Constitution Avenue NW,
Washington DC 20551–0001, not later
than August 13, 2020.
A. Federal Reserve Bank of Chicago
(Colette A. Fried, Assistant Vice
President) 230 South LaSalle Street,
Chicago, Illinois 60690–1414:
1. Forward Mutual Holding Company
and Forward Financial, Inc., both of
Marshfield, Wisconsin; to convert from
bank holding companies to a mutual
holding company and a mid-tier stock
savings and loan holding company,
respectively, by retaining voting shares
of Forward Bank, a state savings
E:\FR\FM\14JYN1.SGM
14JYN1
42402
Federal Register / Vol. 85, No. 135 / Tuesday, July 14, 2020 / Notices
association, also of Marshfield,
Wisconsin, and indirectly engage in real
estate development and management
activities pursuant to section
238.53(b)(4)–(8) of Regulation LL.
Board of Governors of the Federal Reserve
System, July 9, 2020.
Yao-Chin Chao,
Assistant Secretary of the Board.
[FR Doc. 2020–15182 Filed 7–13–20; 8:45 am]
BILLING CODE P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Agency for Healthcare Research and
Quality
Supplemental Evidence and Data
Request on Continuous Positive
Airway Pressure Treatment for
Obstructive Sleep Apnea in Medicare
Eligible Patients
Agency for Healthcare Research
and Quality (AHRQ), HHS.
ACTION: Request for supplemental
evidence and data submissions.
AGENCY:
The Agency for Healthcare
Research and Quality (AHRQ) is seeking
scientific information submissions from
the public. Scientific information is
being solicited to inform our review on
Continuous Positive Airway Pressure
Treatment of Obstructive Sleep Apnea
in Medicare Eligible Patients, which is
currently being conducted by the
AHRQ’s Evidence-based Practice
Centers (EPC) Program. Access to
published and unpublished pertinent
scientific information will improve the
quality of this review.
DATES: Submission Deadline on or
before 30 days after date of publication
of this Notice.
ADDRESSES:
Email submissions: epc@
ahrq.hhs.gov.
Print submissions:
Mailing Address: Center for Evidence
and Practice Improvement, Agency for
Healthcare Research and Quality,
ATTN: EPC SEADs Coordinator, 5600
Fishers Lane, Mail Stop 06E53A,
Rockville, MD 20857.
Shipping Address (FedEx, UPS, etc.):
Center for Evidence and Practice
Improvement, Agency for Healthcare
Research and Quality, ATTN: EPC
SEADs Coordinator, 5600 Fishers Lane,
Mail Stop 06E77D, Rockville, MD
20857.
SUMMARY:
FOR FURTHER INFORMATION CONTACT:
Jenae Benns, Telephone: 301–427–1496
or Email: epc@ahrq.hhs.gov.
VerDate Sep<11>2014
17:58 Jul 13, 2020
Jkt 250001
The
Agency for Healthcare Research and
Quality has commissioned the
Evidence-based Practice Centers (EPC)
Program to complete a review of the
evidence for Continuous Positive
Airway Pressure Treatment of
Obstructive Sleep Apnea in Medicare
Eligible Patients. AHRQ is conducting
this systematic review pursuant to
Section 902(a) of the Public Health
Service Act, 42 U.S.C. 299a(a).
The EPC Program is dedicated to
identifying as many studies as possible
that are relevant to the questions for
each of its reviews. In order to do so, we
are supplementing the usual manual
and electronic database searches of the
literature by requesting information
from the public (e.g., details of studies
conducted). We are looking for studies
that report on Continuous Positive
Airway Pressure Treatment of
Obstructive Sleep Apnea in Medicare
Eligible Patients, including those that
describe adverse events. The entire
research protocol is available online at:
https://www.ahrq.gov/research/
findings/ta/#supplemental.
This is to notify the public that the
EPC Program would find the following
information on Continuous Positive
Airway Pressure Treatment of
Obstructive Sleep Apnea in Medicare
Eligible Patients helpful:
D A list of completed studies that
your organization has sponsored for this
indication. In the list, please indicate
whether results are available on
ClinicalTrials.gov along with the
ClinicalTrials.gov trial number.
D For completed studies that do not
have results on ClinicalTrials.gov, a
summary, including the following
elements: study number, study period,
design, methodology, indication and
diagnosis, proper use instructions,
inclusion and exclusion criteria,
primary and secondary outcomes,
baseline characteristics, number of
patients screened/eligible/enrolled/lost
to follow-up/withdrawn/analyzed,
effectiveness/efficacy, and safety results.
D A list of ongoing studies that your
organization has sponsored for this
indication. In the list, please provide the
ClinicalTrials.gov trial number or, if the
trial is not registered, the protocol for
the study including a study number, the
study period, design, methodology,
indication and diagnosis, proper use
instructions, inclusion and exclusion
criteria, and primary and secondary
outcomes.
D Description of whether the above
studies constitute ALL Phase II and
above clinical trials sponsored by your
organization for this indication and an
SUPPLEMENTARY INFORMATION:
PO 00000
Frm 00057
Fmt 4703
Sfmt 4703
index outlining the relevant information
in each submitted file.
Your contribution is very beneficial to
the Program. Materials submitted must
be publicly available or able to be made
public. Materials that are considered
confidential; marketing materials; study
types not included in the review; or
information on indications not included
in the review cannot be used by the EPC
Program. This is a voluntary request for
information, and all costs for complying
with this request must be borne by the
submitter.
The draft of this review will be posted
on AHRQ’s EPC Program website and
available for public comment for a
period of 4 weeks. If you would like to
be notified when the draft is posted,
please sign up for the email list at:
https://
www.effectivehealthcare.ahrq.gov/
email-updates.
The systematic review will answer the
following questions. This information is
provided as background. AHRQ is not
requesting that the public provide
answers to these questions.
Contextual and Key Questions (KQ)
Contextual Questions
CQ 1: What measures related to
apneas and hypopneas (e.g., apnea
indices, hypopnea indices, and apneahypopnea indices with various
measurements) or other measures (e.g.,
time spent with oxygen saturation
below 90% or other cutoffs,
electrophysiologic signal analysis
metrics such as time and frequency
domain analyses of heart beats) are used
in contemporary research and clinical
settings? How have standard definitions
of these measures changed over time
and what is the explanation for such
changes?
CQ 2: What are commonly used sleep
questionnaires and how have they been
validated?
CQ 3: What treatment modalities for
OSA are currently being marketed in the
U.S.? What OSA treatments
(experimental or approved) are
currently being investigated in ongoing
trials for patients as an alternative to
CPAP?
CQ 4: What are the variable features
of marketed CPAP devices?
CQ 5: What are the patient-centered
health outcome goals and symptom
relief goals of CPAP devices?
Key Questions
KQ 1: What is the efficacy,
effectiveness, comparative effectiveness,
and harms of CPAP devices to improve
clinically significant outcomes?
KQ 1a: How are respiratory
disturbance events (apnea, hypopnea,
E:\FR\FM\14JYN1.SGM
14JYN1
]]>Agencies
[Federal Register Volume 85, Number 135 (Tuesday, July 14, 2020)]
[Notices]
[Pages 42401-42402]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-15182]
-----------------------------------------------------------------------
FEDERAL RESERVE SYSTEM
Formations of, Acquisitions by, and Mergers of Savings and Loan
Holding Companies
The companies listed in this notice have applied to the Board for
approval, pursuant to the Home Owners' Loan Act (12 U.S.C. 1461 et
seq.) (HOLA), Regulation LL (12 CFR part 238), and Regulation MM (12
CFR part 239), and all other applicable statutes and regulations to
become a savings and loan holding company and/or to acquire the assets
or the ownership of, control of, or the power to vote shares of a
savings association.
The public portions of the applications listed below, as well as
other related filings required by the Board, if any, are available for
immediate inspection at the Federal Reserve Bank(s) indicated below and
at the offices of the Board of Governors. This information may also be
obtained on an expedited basis, upon request, by contacting the
appropriate Federal Reserve Bank and from the Board's Freedom of
Information Office at https://www.federalreserve.gov/foia/request.htm.
Interested persons may express their views in writing on whether the
proposed transaction complies with the standards enumerated in the HOLA
(12 U.S.C. 1467a(e)).
Comments regarding each of these applications must be received at
the Reserve Bank indicated or the offices of the Board of Governors,
Ann E. Misback, Secretary of the Board, 20th Street and Constitution
Avenue NW, Washington DC 20551-0001, not later than August 13, 2020.
A. Federal Reserve Bank of Chicago (Colette A. Fried, Assistant
Vice President) 230 South LaSalle Street, Chicago, Illinois 60690-1414:
1. Forward Mutual Holding Company and Forward Financial, Inc., both
of Marshfield, Wisconsin; to convert from bank holding companies to a
mutual holding company and a mid-tier stock savings and loan holding
company, respectively, by retaining voting shares of Forward Bank, a
state savings
[[Page 42402]]
association, also of Marshfield, Wisconsin, and indirectly engage in
real estate development and management activities pursuant to section
238.53(b)(4)-(8) of Regulation LL.
Board of Governors of the Federal Reserve System, July 9, 2020.
Yao-Chin Chao,
Assistant Secretary of the Board.
[FR Doc. 2020-15182 Filed 7-13-20; 8:45 am]
BILLING CODE P
